西咪替丁辅助治疗直肠癌的临床应用研究

Cimetidine as adjuvant treatment in rectal cancer

为探讨西咪替丁辅助治疗直肠癌的临床价值,将行直肠癌根治术患者60例随机分为对照组和西咪替丁治疗组各30例。治疗组术前1周开始服用西咪替丁0.2g,4次/d;术后1～7d继续应用西咪替丁静脉推注0.4g,2次/d;术后第8天后继续服用西咪替丁0.2g,4次/d,持续2年。对照组与治疗组术均应用CF/5-FU辅助化疗6个疗程,统计治疗组和对照组的5年累积生存率并进行统计学分析。西咪替丁治疗组中位生存期56个月,5年累积生存率为20.5%;对照组中位生存期50.5个月,5年累积生存率为34.0%。两组5年累积生存率差异无统计学意义(χ2=2.892,P=0.089)。初步研究结果提示,西咪替丁辅助治疗直肠癌未能明显提高直肠癌患者的术后生存率。

To study the influence of cimetidene on survival in patients with rectal carcinoma. Data of 60 patients were underwent resection for rectal cancer from March 2001 to July 2003. 60 patients were randomized into treatment group of 30 patients who took cimetidene 7 days before curative surgery till 2 years postoperation, and control group of 30 patients who received similar treatment except for cimetidine intervention. In cimetidine group, 0.8 g of cimetidine was administered daily, beginning a week before operation for a total of two years. Both group were treated with CF/5-FU therapy postoperation. The patients＇ survival rate were analyzed. The median survival term was 56 months and the 5 year overall survival rate was 20.5 % in the eimetidine treatment group; The median survival term was 50.5 months and the 5-year overall survival rate was 34.0% in the control group. There was no significant difference in 5-year overall survival rate between the two groups （X^2 =2. 892, P=0. 089）. In conclusions, cimetidine did not show significant survival benefit in rectal cancer patients.